CYKLX Drug Patent Profile

Which patents cover Cyklx, and when can generic versions of Cyklx launch?

Cyklx is a drug marketed by Thea Pharma and is included in one NDA. There are three patents protecting this drug.

This drug has fifteen patent family members in eleven countries.

The generic ingredient in CYKLX is articaine hydrochloride. There are seven drug master file entries for this compound. Additional details are available on the articaine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Cyklx

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 15, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for CYKLX

International Patents:	15
US Patents:	3
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CYKLX

CYKLX is protected by three US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW PRODUCT.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Thea Pharma	CYKLX	articaine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218643-001	Aug 15, 2025		DISCN	Yes	No			Y
Thea Pharma	CYKLX	articaine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218643-001	Aug 15, 2025		DISCN	Yes	No
Thea Pharma	CYKLX	articaine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218643-001	Aug 15, 2025		DISCN	Yes	No			Y
Thea Pharma	CYKLX	articaine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218643-001	Aug 15, 2025		DISCN	Yes	No			Y

International Patents for CYKLX

See the table below for patents covering CYKLX around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2020245203	Anesthetic composition and method of anesthetizing the eye
Australia	2025252666	Anesthetic composition and method of anesthetizing the eye
Brazil	112021019039	Composição anestésica e método de anestesia do olho
Canada	3134531	COMPOSITION ANESTHESIQUE ET PROCEDE D'ANESTHESIE DE L'OEIL (ANESTHETIC COMPOSITION AND METHOD OF ANESTHETIZING THE EYE)
China	114072139	麻醉组合物和麻醉眼睛的方法 (ANESTHETIC COMPOSITION AND METHOD OF ANESTHETIZING THE EYE)
European Patent Office	3946311	COMPOSITION ANESTHÉSIQUE ET PROCÉDÉ D'ANESTHÉSIE DE L'IL (ANESTHETIC COMPOSITION AND METHOD OF ANESTHETIZING THE EYE)
Israel	286624	תכשיר אלחוש ושיטת אלחוש העין (Anesthetic composition and method of anesthetizing the eye)

Investment Scenario and Fundamentals Analysis for CYKLX

Last updated: February 20, 2026

CYKLX (Cyclacel Pharmaceuticals, Inc.) is a clinical-stage biotech company developing therapies primarily targeting cancer and hematologic disorders. Its pipeline includes proprietary compounds progressing through early to late-stage clinical trials.

Company Overview and Market Position

CYKLX focuses on cyclin-dependent kinase (CDK) modulators. Its lead candidate, CYC065, is an orally administered CDK2/9 inhibitor evaluated for treating multiple cancer types. The company aims to position itself within niche oncology indications like glioblastoma, non-small cell lung cancer, and hematologic malignancies.

Clinical Pipeline and Development Status

Product Candidate	Indication	Development Stage	Mechanism
CYC065	Multiple cancers	Phase 1/2 trials	CDK2/9 inhibitor
Sapacitabine (SECTROLIX)	Leukemia, myelodysplastic syndromes	Phase 3	Nucleoside analogue

CYC065 has shown early signs of efficacy and acceptable safety profile in initial trials but lacks confirmatory data. Sapacitabine is in late-stage development for hematologic diseases but faces competition from established therapies.

Financials and Funding

CYKLX reported recent financials indicating limited revenue due to its stage:

• Revenue: $-4.2 million (Q2 2023)
• R&D expenses: $12 million (Q2 2023)
• Cash and equivalents: approximately $30 million as of Q2 2023

Long-term survival hinges on successful clinical outcomes and securing licenses or partnerships.

Regulatory and Clinical Risks

• Clinical Trial Outcomes: The success depends on efficacy signals in intermediate phases. Failure could lead to substantial valuation decline.
• Regulatory Approval: No drugs currently approved by FDA or EMA. The path to approval is uncertain.
• Competition: Standard-of-care therapies for targeted indications may limit market penetration and pricing.

Market and Competitive Landscape

Indication	Market Size (USD)	Key Competitors	Competitive Edge
Glioblastoma	~$1.2 billion (2022)	Temozolomide, Bevacizumab	Novel mechanism in early trials
Leukemia	~$8 billion (2022)	Lenalidomide, Azacitidine	Focus on resistant cases

The market expects expansion with novel mechanisms addressing unmet needs, like CDK inhibitors, but success requires clear clinical benefits over existing options.

Investment Considerations

Pros:

• Innovative mechanism targeting difficult cancers
• Early-stage pipeline that could generate significant upside if successful

Cons:

• No FDA approvals yet, high clinical and regulatory risk
• Limited financial runway with ongoing R&D expenses
• Competitive landscape with established therapies

Valuation and stock performance

As of Q3 2023, CYKLX trades around $1.20 per share with a market capitalization near $100 million. The stock remains highly volatile, with significant swings tied to clinical trial news and partnership developments. Its valuation reflects high risk, high potential.

Key Milestones to Watch

• Phase 2 data readouts for CYC065
• Partnership or licensing agreements
• Upcoming clinical trial initiations or completions
• Regulatory submissions and potential breakthrough therapy designations

Summary

CYKLX presents an early-stage investment primarily driven by its pipeline progress and clinical trial results. Its prospects depend on positive efficacy and safety data, competitive positioning, and the ability to establish partnerships that can fund further development. The company's financial position requires careful monitoring as it advances its clinical programs.

---

Key Takeaways

• CYKLX operates in niche oncology with a focus on CDK inhibition.
• It bears high clinical and regulatory risks typical of biotech startups.
• The pipeline has potential but warrants wait-and-see for trial data.
• Financial health remains fragile; partnership signals could influence valuation.
• Market size and unmet medical needs support long-term upside rather than immediate profitability.

---

5 FAQs

Q1: What is CYKLX’s most advanced product candidate?
A1: CYC065 is the lead candidate currently in Phase 1/2 trials for various cancers.

Q2: What are the main risks for investing in CYKLX?
A2: Risks include clinical trial failures, lack of regulatory approval, competition, and limited financial resources.

Q3: How does CYKLX compare with competitors?
A3: It offers a novel mechanism with potential advantages in resistant cancers but lacks market presence and proven efficacy.

Q4: What is the company’s financial outlook?
A4: CYKLX’s finances are constrained, with negative revenue and ongoing R&D expenses, relying on cash reserves and potential deals.

Q5: When are key catalysts expected?
A5: Clinical trial results for CYC065, partnership announcements, and potential regulatory milestones are upcoming catalysts.

---

References

1. Cyclacel Pharmaceuticals. (2023). Quarterly financial report Q2 2023. [Company filings].
2. Pharmaprojects. (2023). Pipeline analysis of cyclin-dependent kinase inhibitors.
3. MarketsandMarkets. (2022). Oncology market size estimation.